Komori
Management planning4582SymBio Pharmaceuticals LimitedPharmaceuticals

Establishment of a stable supply system toward commercialization of an ultra-high-sensitivity (pico-level) immunochromatography system

Entered into a supply agreement for nanocomposite particles with 日鉄ケミカル&マテリアル and a manufacturing and supply agreement for ultra-high-sensitivity test kits with ニッポンジーン, establishing a stable supply system for commercialization. There will be no impact on consolidated results for the fiscal year ending December 2026.

Worth reading
7Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Improvement
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Conditional
How definitive the wording is.

Items stated in the management plan

Publication date18 May 2026

This document does not state the plan name, plan period, or numerical targets.

Key initiatives
01Commercialization of the system
02Advancing the business through partnerships with optimal partners in each field
Items stated in the management plan
ItemDetails
Key initiativesCommercialization of the system, Advancing the business through partnerships with optimal partners in each field
Publication date18 May 2026
Items this document does not state (23)
Plan namePlan periodProgress against the planSales TargetOperating profit targetOperating profit margin targetNet income targetROE targetROIC targetPayout ratio / DOE policyTreasury share acquisition policyCost of capitalSelf-assessment of PBR and share priceTotal investment planInvestment amount by sectorSegment targetNon-financial targetsPlan assumptionsResults under the previous planReason for revision or withdrawalSize of the Target MarketRisks identifiedDate of board resolution

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To establish a supply chain capable of stable supply of the system and advance its commercialization. Specialized expertise and infrastructure in diagnostic technology, manufacturing and quality control are essential, and the company has also indicated its policy of advancing the business through partnerships with optimal partners in each field.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Establishment of a stable supply system toward commercialization of an ultra-high-sensitivity (pico-level) immunochromatography system | SymBio Pharmaceuticals Limited (4582) timely disclosure | Komori